A Phase II Study Evaluating Safety and Efficacy of Niraparib in Patients With Previously Treated Homologous Recombination (HR) Defective or Loss of Heterozygosity (LOH) High Metastatic Esophageal/Gastroesophageal Junction/Proximal Gastric Adenocarcinoma

Status: Closed to Accrual

Learn more:

• https://clinicaltrials.gov/study/NCT03840967
• News release

Abstracts/Posters/Presentations:

• H Mamdani, R Mehta, C Fountzilas, M Radovich, S Perkins, SI Jalal. A phase II study evaluating safety and efficacy of niraparib in patients with previously treated homologous recombination (HR) defective or loss of heterozygosity (LOH) high-metastatic esophageal/GEJ/proximal gastric adenocarcinoma. Presented as Trials In Progress Poster at the 2020 Gastrointestinal Cancers Symposium, January 23, 2020. J Clin Oncol 38, 2020 (suppl 4; abstr TPS472). See abstract.

Study Contact: studies@hoosiercancer.org; (317) 921-2050.